CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-0.95%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.59B
AUM Growth
+$2.59B
(-3.6%)
Cap. Flow
-$10M
Cap. Flow
% of AUM
-0.39%
Top 10 Holdings %
Top 10 Hldgs %
61.39%
Holding
42
New
6
Increased
10
Reduced
14
Closed
4
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$98.8M |
| 2 |
Gilead Sciences
GILD
|
$83.5M |
| 3 |
Merck
MRK
|
$76.6M |
| 4 |
Incyte
INCY
|
$66.1M |
| 5 |
Viatris
VTRS
|
$54.1M |
Top Sells
| 1 |
Tenet Healthcare
THC
|
$127M |
| 2 |
HCA Healthcare
HCA
|
$109M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$68.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$33.8M |
| 5 |
Alkermes
ALKS
|
$33.1M |
Sector Composition
| 1 | Healthcare | 96.7% |
| 2 | Technology | 3.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Teva Pharmaceuticals
TEVA
$21.5B
| $22M | 0.76% |
2,750,000
-2,250,000
| -45% | -$18M |
|
27
Collegium Pharmaceutical
COLL
$1.25B
| $19.6M | 0.67% |
1,050,000
-950,000
| -48% | -$17.7M |
|
28
Zymeworks
ZYME
$1.07B
| $13.1M | 0.45% |
800,000
+50,000
| +7% | +$820K |
|
29
Inogen
INGN
$213M
| $6.8M | 0.23% |
+200,000
| New | +$6.8M |
|
|
TECX
30
Tectonic Therapeutic, Inc. Common Stock
TECX
$305M
| $6.29M | 0.22% |
1,633,333
-1,500,000
| -48% | -$5.77M |
|
31
Puma Biotechnology
PBYI
$258M
| $6.23M | 0.21% |
2,050,000
-1,375,000
| -40% | -$4.18M |
|
32
Theravance Biopharma
TBPH
$691M
| $5.53M | 0.19% |
500,000
-2,000,000
| -80% | -$22.1M |
|
|
NUVA
33
DELISTED
NuVasive, Inc.
NUVA
| $5.25M | 0.18% |
+100,000
| New | +$5.25M |
|
34
Glaukos
GKOS
$5.42B
| $3.33M | 0.11% |
+75,000
| New | +$3.33M |
|
35
InnovAge Holding
INNV
$509M
| $1.75M | 0.06% |
350,000
-650,000
| -65% | -$3.25M |
|
|
SDC
36
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
| $999K | 0.03% |
+425,000
| New | +$999K |
|
37
AstraZeneca
AZN
$255B
| – | – |
0
| – | – |
|
|
38
HCA Healthcare
HCA
$95.4B
| – | – |
-447,500
| Closed | -$109M |
|
39
iRhythm Technologies
IRTC
$5.67B
| – | – |
-475,000
| Closed | -$27.8M |
|
40
Novartis
NVS
$248B
| – | – |
0
| – | – |
|
|
RETA
41
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| – | – |
-685,000
| Closed | -$68.9M |
|
|
RDUS
42
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-1,500,000
| Closed | -$18.6M |
|